aTYR PHARMA INC Debt Securities, Available-for-sale, Amortized Cost
aTYR PHARMA INC (ATYR) had Debt Securities, Available-for-sale, Amortized Cost of $41.28 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-07
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $41.28M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $56.52M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $67.90M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $84.00M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $41.28M 10-Q · filed 2026-08-07 |
| 2026-03-31 | $56.52M 10-Q · filed 2026-05-15 |
| 2025-12-31 | $67.90M 10-Q · filed 2026-08-07 |
| 2025-09-30 | $84.00M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $63.15M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $66.00M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $61.06M 10-K · filed 2026-03-05 |
| 2024-09-30 | $54.44M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $71.80M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $77.80M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $75.65M 10-K · filed 2025-03-13 |
| 2023-09-30 | $92.59M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $96.55M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $93.89M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $56.55M 10-K · filed 2024-03-14 |
| 2022-09-30 | $59.63M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $80.83M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $91.05M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $105.79M 10-K · filed 2023-03-14 |
| 2021-09-30 | $56.63M 10-Q · filed 2021-11-12 |
| 2021-06-30 | $41.88M 10-Q · filed 2021-08-11 |
| 2021-03-31 | $38.06M 10-Q · filed 2021-05-14 |
| 2020-12-31 | $14.73M 10-K · filed 2022-03-15 |
| 2020-09-30 | $17.99M 10-Q · filed 2020-11-13 |
| 2020-06-30 | $19.80M 10-Q · filed 2020-08-13 |
| 2019-12-31 | $21.92M 10-K · filed 2021-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |